Areas of Special Interest
|C. Michael Cotten, MD, MHS, Chief||Use of cord blood therapy for perinatal asphyxia; use of genomic studies to diagnose and guide neonatal therapy|
|Eric Benner, MD, PhD||Neural stem cell fate determination with a focus on oligodendrocyte specification following premature birth or perinatal brain injury; technology to noninvasively control neural circuits during development to investigate how altered neural activity impacts oligodendrocyte maturation; novel therapeutic approaches to mitigate myelin injury in high-risk infant population|
|Margarita Bidegain, MD, MHS||Perinatal and neonatal palliative care, health disparities in perinatal care, neonatal sepsis and antibiotics, neuro neonatal intensive care|
|Erica Davis, PhD||Functional interpretation of variation at the DNA level beyond the resolution of genetics arguments; mapping pathogenic alleles back to disease phenotypes|
|Jeffrey Ferranti, MD, MS||Use of medical informatics, computerized patient safety initiatives|
|Kimberley Fisher, PhD, FNP-BC||Use of cord blood therapy for perinatal asphyxia; evidence-based practices and management of clinical research in the NICU environment|
|Ronald N. Goldberg, MD||Perinatal asphyxia; use of stem cell/cord blood therapy for perinatal asphyxia|
|Rachel Greenberg, MD, MHS||
Pharmacology and infectious diseases in infants, differences in drug dosing between infants and older children and adults, drug safety and efficacy in infants, the impact of infection on infants in the neonatal intensive care unit, strategies to reduce the risk for developing infections in infants
|Mary Hutson, PhD||
Developmental mechanisms of congenital heart defects: neural crest and conotruncal defects; signaling mechanisms underlying outflow tract development and conotruncal defects; ion channel signaling in cardiovascular development; maternal fever-associated heart defects including double outlet right ventricle, tetralogy of Fallot and supravalular stenosis; and hypoplastic left heart syndrome and calcium signaling
|Lawrence Ku, MD||
Infant clinical pharmacology, including safety and efficacy of drugs administered to critically ill infants; use of pharmacometrics to improve medical therapies in infants; role of infant drug metabolism in drug interactions
|Chay Kuo, MD, PhD||Neurodevelopmental research of neural stem cells|
|William Malcolm, MD||Diagnosis and management of gastroesophageal reflux|
|P. Brian Smith, MD, MHS||
Neonatal pharmacology, drug safety, environmental factors impacting child health, nosocomial infections, neonatal candidiasis
|David T. Tanaka, MD||Health care economics|
- Problems of low birth weight infants, morbidity and mortality, perinatal asphyxia, ventilatory management, growth and development of high-risk infants, and the role of genomics in neonatal morbidity
- Neurodevelopmental outcomes of high-risk infants.
- Causes of birth defects that particularly affect the cardio-craniofacial field and left-right cardiac axis determination
- Perinatal mechanisms of disrupted development and post-natal injury with special emphasis on lung, brain, and heart
- Neonatal pulmonary hypertension, pulmonary injury, and lung function
Health Care Economics Research
- Medical economics, and biomedical engineering, specifically, in the areas of informatics, optics, virtual reality and microdigital fluidics
The Jean and George Brumley Jr. Neonatal Perinatal Research Institute (NPRI)
The Jean and George Brumley Jr. Neonatal Perinatal Research Institute (NPRI) aims to provide a dedicated environment wherein investigators from different fields can participate in collaborative multidisciplinary research aimed at understanding the basis of key problems suffered by neonates.
National Institute of Child Health and Human Development (NICHD) Neonatal Research Network
The Duke Division of Neonatology is a member of the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, a consortium of the leading neonatal intensive care units in the country that perform cutting-edge, collaborative clinical research.
Clinical Trials - Neonatal-Perinatal Research Unit (NPRU)
In the Division of Neonatology, we continually seek to improve health care practices by conducting clinical research, which includes our membership with the NICHD. We have many ongoing clinical trials in our Intensive Care Nursery (ICN). The Neonatal-Perinatal Research Unit (NPRU) provides the professional infrastructure to complete these studies. The operations director of the NPRU is Kimberley Fisher, PhD. Dr. Fisher is assisted by six study coordinators as well as other support staff that contribute to the success of clinical trials.